Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25554343 | 1.00 | CYP2D6 (0.54) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL8972253 | 0.87 | CYP2D6 (0.63) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL27426180 | 0.87 | CYP2D6 (0.63) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL17034685 | 0.87 | CYP1A2 (0.50) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL4766284 | 0.86 | CA1 (0.47) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL25319889 | 0.83 | CA1 (0.47) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL25319893 | 0.83 | CA1 (0.47) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL29689264 | 0.82 | CYP2D6 (0.53) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL2385474 | 0.82 | CYP2D6 (0.53) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL1369011 | 0.82 | CYP2D6 (0.53) | CYP2D6CA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250084094-A1 | SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2025-03-13 | — | — | US | disclosed |
| US-20240368180-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2024-11-07 | — | — | US | disclosed |
| EP-4440697-A1 | SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118632850-A | Spirocyclic inhibitors of APOL1 and methods of use thereof | 弗特克斯药品有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118574809-A | 4-Phenyl-2- (1H-1, 2, 3-triazol-4-yl) piperidin-4-ol derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4392426-A1 | SOLID FORMS OF SPIROTRICYCLIC APOL1 INHIBITORS AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
| WO-2023101981-A1 | SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102022-A1 | 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230119114-A1 | SOLID FORMS OF APOL1 INHIBITORS AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-04-20 | — | — | US | disclosed |
| WO-2023028237-A1 | SOLID FORMS OF SPIROTRICYCLIC APOL1 INHIBITORS AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2022047031-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | CYP2D6 4077/4885CA1 4795/4885CA2 4830/4885 |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | CYP2D6 4077/4885CA1 4795/4885CA2 4830/4885 |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, RNASE1 | CYP2D6 4147/4885CA1 4804/4885CA2 4782/4885 |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | APOL1, RNASE1, LOXL1 | CYP2D6 2199/4885CA1 4248/4885CA2 3764/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | CYP2D6 2583/4885CA1 4869/4885CA2 4828/4885 |
| US-20240368180-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | CYP2D6 4077/4885CA1 4795/4885CA2 4830/4885 |
| US-20230119114-A1 | SOLID FORMS OF APOL1 INHIBITORS AND METHODS OF USING SAME | APOL1, MLKL, SAAL1 | CYP2D6 1702/4885CA1 4535/4885CA2 3994/4885 |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | CYP2D6 4077/4885CA1 4795/4885CA2 4830/4885 |
| US-20250084094-A1 | SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, FMNL1 | CYP2D6 2750/4885CA1 4318/4885CA2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.